Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AHS 2022 | The development of more targeted therapies for headache

Lauren Natbony • 16 Jun 2022
AHS 2022
Headache

Lauren Natbony, MD, Icahn School of Medicine, New York, NY, discusses unanswered questions in headache care and treatment. CGRP is the protein that has most recently been studied for targeted medication – however, with some individuals not responding well to CGRP targeted medications, it is evident that other proteins are driving migraine attacks. Therefore, there is a need for a greater understanding of individual biochemistry – allowing for more targeted therapies. This interview took place during the 2022 American Headache Society (AHS) Annual Scientific Meeting in Denver, CO.

More from Lauren Natbony

Lifestyle management and recommendations in headache care
6:01
Lifestyle management and recommendations in headache care
Lauren Natbony • 7 Jun 2022
Future work on lifetyle recommendations in headache care
1:40
Future work on lifetyle recommendations in headache care
Lauren Natbony • 16 Jun 2022
Challenges in infant headache care
0:53
Challenges in infant headache care
Lauren Natbony • 16 Jun 2022
Current recommendations on lifestyle management in headache care
2:47
Current recommendations on lifestyle management in headache care
Lauren Natbony • 16 Jun 2022

Related Videos

TRIPLE study: triple combination therapy for chronic migraine
2:41
TRIPLE study: triple combination therapy for chronic migraine
Marina Romozzi • 27 Jun 2026
PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
5:05
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
Richard Lipton • 1 Jul 2026
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
8:49
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
Richard Lipton • 1 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals